What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2022-03-14 compared with 2021-03-12 · 223 added, 187 removed, 153 unchanged (73% of the section changed)

Unless otherwise indicated or the context otherwise requires, references to the Company, ChromaDex, we, us and our refer to ChromaDex Corporation and its consolidated subsidiaries.

Company Background

On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc.

Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation.

On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation.

ChromaDex Corporation was traded on the over-the-counter market under the symbol “CDXC.” On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market under the symbol “CDXC.”

ChromaDex, Inc., a wholly owned subsidiary of ChromaDex Corporation, was originally formed as a California corporation on February 19, 2000.

On March 12, 2017, ChromaDex Corporation acquired Healthspan Research LLC, a consumer product company offering TRU NIAGEN® branded products.

This marked the strategic shift to become a global bioscience company dedicated to healthy aging.

On September 5, 2017, the Company completed the sale of its operating assets that were used with the Company’s quality verification program testing and analytical chemistry business for food and food related products to Covance Laboratories Inc.

On January 15, 2021, Healthspan Research LLC was dissolved.

Prior to its dissolution, Healthspan Research, LLC contributed its assets and liabilities to ChromaDex, Inc.

Company Overview

ChromaDex is a global bioscience company dedicated to healthy aging.

The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (“NAD+”), levels of which decline with age.

NAD+ is an essential coenzyme and a key regulator of cellular metabolism.

Our team, which includes world-renowned scientists, is pioneering research pertaining to nicotinamide adenine dinucleotide (NAD+) which is found in every cell of human bodies and levels of which decline with age.

NAD+ is an essential coenzyme, a key regulator of cellular metabolism and is required for mitochondria to function efficiently.

Best known for its role in cellular energy production, NAD+ is now thought to play an important role in healthy aging.

1 unchanged sentence

NAD+ levels are not constant, and in humans, NAD+ levels have been shown to decline by more than 50% from young adulthood to middle age.

NAD+ continues to decline as humans grow older.

There are other causes of NAD+ depletion, such as poor diet, alcohol consumption and a number of disease states.

NAD+ levels may also be increased, including through calorie restriction and moderate exercise.

There are other factors linked to NAD+ depletion, including poor diet, excess alcohol consumption and a number of disease states.

NAD+ levels may also be increased, including through calorie restriction, moderate exercise and supplementation with NAD+ precursors, such as nicotinamide riboside (NR).

Healthy aging, mitochondrial health and NAD+ continue to be areas of focus in the research community.

As of 2020, there were over 350 published human clinical studies related to NAD+.

The areas of study include understanding NAD+’s role in Alzheimer’s disease, Parkinson’s disease, neuropathy and heart failure.

In 2013, ChromaDex commercialized NIAGEN® nicotinamide riboside (“NR”), a novel form of vitamin B3.

Data from numerous preclinical studies, and confirmed in human clinical trials, show that NR is a highly efficient NAD+ precursor that significantly raises NAD+ levels.

To date, there are over 450 published human clinical studies related to NAD+ and its impact on health.

Areas of study include understanding NAD+’s role in Alzheimer’s disease, Parkinson’s disease, neuropathy, sarcopenia, liver disease and heart failure.

In 2013, we commercialized NIAGEN®, a proprietary form of NR, a novel form of vitamin B3.

Data from numerous preclinical studies, and confirmed in human clinical trials, show that NR is a highly efficient NAD+ precursor that significantly raises blood and tissue NAD+ levels.

NIAGEN® is safe for human consumption.

NIAGEN® has twice been successfully reviewed under the U.S.

Food and Drug Administration’s new dietary ingredient (“NDI”) notification program, has been successfully notified to the U.S.

Food and Drug Administration (the “FDA”) as generally recognized as safe (“GRAS”), and has been approved as safe by Health Canada, the European Commission and the Therapeutic Goods Administration of Australia.

Clinical studies of NIAGEN® have demonstrated a variety of outcomes including increased NAD+ levels, increased cellular metabolism and increased energy production.

NIAGEN® is the trade name for our proprietary ingredient NR, and is protected by patents to which we are the exclusive licensee.

NIAGEN® has twice been successfully reviewed under the United States (U.S.) Food and Drug Administration’s (FDA) new dietary ingredient (NDI) notification program, it has been successfully notified to the FDA as generally recognized as safe (GRAS), and has been approved by Health Canada, the European Commission and the Therapeutic Goods Administration of Australia.

Clinical studies of NIAGEN® have demonstrated a variety of outcomes including increased NAD+ levels, altered body composition, increased cellular metabolism and increased cellular energy production.

NIAGEN® is protected by patents to which we are the owner or have exclusive rights.

ChromaDex is among the world leaders in the emerging NAD+ space.

ChromaDex has amassed more than 200 research partnerships with leading universities and research institutions around the world including the National Institutes of Health, Cornell, Dartmouth, Harvard, Massachusetts Institute of Technology, University of Cambridge and the Mayo Clinic.

We have amassed more than 245 research partnerships with leading universities and research institutions around the world including the National Institutes of Health, Cornell, Dartmouth, Harvard, Massachusetts Institute of Technology, University of Cambridge and the Mayo Clinic.

Additional relationships are currently being developed.

1 unchanged sentence

Roger Kornberg, Nobel Laureate Stanford Professor, Dr.

Charles Brenner, one of the world’s recognized experts in NAD+ and inventor of nicotinamide riboside, Dr.

Rudy Tanzi, the co-chair of the department of neurology at Harvard Medical School and one of the world’s leading experts in food and nutrition, Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, Dr.

Charles Brenner, one of the world’s recognized experts in NAD+ and discoverer of NR as a NAD+ precursor and chair of the Department of Diabetes & Cancer Metabolism at the City of Hope National Medical Center, Dr.

Rudy Tanzi, the co-chair of the department of neurology at Harvard Medical School, Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, Dr.

Bruce German, Chairman of food, nutrition and health at the University of California, Davis, Dr.

1 unchanged sentence

David Katz, the Founder and former director of Yale University’s Yale-Griffin Prevention Research Center;

President and Founder of the non-profit True Health Initiative;

and Founder and Chief Executive Officer of Diet ID, Inc.

STRATEGIC SHIFT TO GLOBAL CONSUMER PRODUCT COMPANY

3 unchanged sentences

Watson Group, in 2017, followed by the launch in Singapore in 2018.

In 2018, we also launched TRU NIAGEN® in New Zealand with retail partner Matakana Superfoods and in Canada by making it available at www.truniagen.ca and to healthcare practitioners at Fullscript Canada after receiving regulatory approval for sale from Health Canada.

We are currently selling cross border in China on Tmall, JD.com, Kaola.com and Wechat and on Amazon in Canada, Japan, the United Kingdom, Germany, France, Italy, Spain, Netherlands and Sweden.

In 2019, we received a positive opinion from the European Food Safety Authority on NR as a novel food ingredient for use in food supplement and approval from the Australian Therapeutic Goods Association (“TGA”) for use in listed complementary medicines.

With the TGA approval we extended our partnership with our New Zealand partner, Matakana Superfoods, to also include Australia.

We will continue to focus on obtaining additional regulatory approvals required to expand our marketing and distribution of our TRU NIAGEN® brand in new strategic international markets.

In 2018, we also launched TRU NIAGEN® in New Zealand with retail partner Matakana Superfoods as well as in Canada by making it available at www.truniagen.ca and to healthcare practitioners at Fullscript Canada after receiving regulatory approval for sale as a natural health product from Health Canada.

In 2019, we received approval from the Australian Therapeutic Goods Association (TGA) for use in listed complementary medicines.

With TGA approval we extended our partnership with our New Zealand partner, Matakana Superfoods, to also include Australia.

In 2020, we received approval of NR as a novel food ingredient for use in food supplements from the European Commission, which followed a positive opinion from the European Food Safety Authority in 2019.

We are currently selling on Amazon in Canada, Japan, the United Kingdom, Germany, France, Italy, Spain, Poland, Netherlands and Sweden and selling cross-border in China on Tmall, JD.com and Wechat.

Additionally, in June 2021, we began distributing Tru Niagen® in 3,800+ U.S.

Walmart stores.

We continue to focus on expanding marketing and distribution of our TRU NIAGEN® brand in new strategic international markets, domestic channels, and secure regulatory approvals needed to accomplish the same.

INGREDIENTS AND ANALYTICAL REFERENCE STANDARDS AND SERVICES BUSINESS SEGMENTS

4 unchanged sentences

In 2020, we received an additional one-time fee of $1.0 million, following the launch of the products in the United States.

Nestlé will potentially pay us multiple one-time fees for a total aggregate payment up to $6.0 million in product launch fees, following the launch of the products in certain territories.

We are a leading provider of research and quality-control products and services to the natural products and life science industries.

1 unchanged sentence

We have conducted this analytical reference standards and services business since 1999.

For the fiscal years ended December 31, 2020 and December 31, 2019, our revenues were approximately $59.3 million and $46.3 million, respectively.

The following table summarizes the Company’s total sales for each of the business segments in the last two years.

Please refer to Item 8 Financial Statements and Supplementary Data of this Form 10-K for additional financial information for each of the business segments.

For the years ended December 31, 2021 and 2020, our net sales were approximately $67.4 million and $59.3 million, respectively.

The following table summarizes total net sales for each of our business segments in the last two years.

Please refer to Item 8 Financial Statements and Supplementary Data of this Form 10-K for additional financial information about each of our business segments.

Year Ended December 31,

(In thousands) 2021 2020

Consumer Products Segment $ 56,705 $ 47,090

Ingredients Segment 7,407 9,198

Analytical Reference Standards and Services Segment 3,337 2,969

$47.1 million

$59.3 million

$36.1 million

$46.3 million

Company Background

On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (“Cody”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (“Acquisition Sub”), and ChromaDex, Inc.

(the “Merger”).

Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation.

On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation.

ChromaDex Corporation was traded on the Over the Counter market under the symbol “CDXC.” On April 25, 2016, ChromaDex Corporation became listed on the NASDAQ Capital Market under the symbol “CDXC.”

ChromaDex, Inc., a wholly owned subsidiary of ChromaDex Corporation, was originally formed as a California corporation on February 19, 2000.

On March 12, 2017, ChromaDex Corporation acquired Healthspan Research LLC, a consumer product company offering TRU NIAGEN® branded products.

This marked the strategic shift to become a global, science-based bioscience company dedicated to healthy aging.

On January 15, 2021, Healthspan Research LLC was dissolved.

Prior to its dissolution, Healthspan Research, LLC contributed its assets and liabilities to ChromaDex, Inc.

Total net sales $ 67,449 $ 59,257

Business Market

According to the data from Global Wellness Institute, the global wellness industry market was approximately $4.5 trillion in 2018.

Personal care, beauty and anti-aging market was approximately $1.1 trillion, healthy eating, nutrition and weight loss was approximately $702 billion and traditional and complementary medicine market was approximately $360 billion.

According to the data from Grand View Research, the global dietary supplements market size was estimated at $123 billion in 2019, and is expected to grow at a CAGR of 8.2% to about $231 billion by 2027.

According to the data from Global Wellness Institute, the global wellness industry market was approximately $4.4 trillion in 2020 amidst the disruptions of COVID-19, which is down from $4.9 trillion in 2019.

In 2020, the Personal care, beauty and anti-aging market was approximately $960 billion, healthy eating, nutrition and weight loss was approximately $950 billion and traditional and complementary medicine market was approximately $410 billion.

The Global Wellness Institute projects the overall wellness economy to grow approximately 10% annually, or 60% in total, from 2020 to 2025, with most segments projected to exceed GDP growth.

According to the data from Grand View Research, the global dietary supplements market size was estimated at $140 billion in 2020, and is expected to grow at a compound annual growth rate of 8.6% to about $271 billion by 2028.

Business Model

CONSUMER PRODUCTS SEGMENT

Our business model is to sell TRU NIAGEN® to consumers worldwide.

As one of the world leaders in the emerging NAD+ space and the science of aging, we will continue to seek to discover and enhance patented technology and evolve our TRU NIAGEN® products to potentially improve health by safely raising NAD+ levels.

Our principal objective is to sell and increase awareness of TRU NIAGEN® to consumers worldwide.

As one of the world leaders in the emerging NAD+ space and the science of healthy aging, we continuously strive to evolve our TRU NIAGEN® products with the aim of potentially improving consumers health by safely raising NAD+ levels.

Further, we seek to continue exploration, discovery and enhancement of patented technologies.

The TRU NIAGEN® brand is built on scientific evidence, trust and the direct impact to our consumers of aging better.

We intend to expand to the worldwide NAD+-related healthy aging market by entering into new international markets.

We will continue to focus on obtaining additional regulatory approvals required to expand our marketing and distribution of our TRU NIAGEN® products in new international markets.

We will utilize our proprietary ecommerce platforms, and the ecommerce and brick and mortar platforms of strategic regional and local partners.

Our United States (“U.S.”) based business will continue to support our global operations, including:

We maintain our focus of obtaining additional regulatory approvals required to expand marketing and distribution efforts of our TRU NIAGEN® products in new international markets.

We will utilize our proprietary e-commerce platforms, and the e-commerce and brick and mortar platforms of strategic regional and local partners.

based business will continue to support our global operations through the following:

• Corporate development and strategy

2 unchanged sentences

• Multi-platform global marketing campaigns and know-how

Build and evolve propriety ecommerce platform and data analytics

Global manufacturing and supply chain operations

• Propriety e-commerce platform and data analytics

• Global manufacturing and supply chain operations management

We expect to continue to supply our international operations with finished products manufactured in the U.S, and to continue to provide all our marketing materials and know-how to our international strategic partners.

5 unchanged sentences

We have taken advantage of both supply chain needs and regulatory requirements to build our analytical reference standards and services segment.

We believe that we create value throughout the supply chain of the dietary supplements, functional foods, life science research, and personal care markets.

We believe we create value throughout the supply chain of the dietary supplements, functional foods, life science research, personal care markets and associated analytical testing laboratories.

We intend to capitalize on additional opportunities in product development and commercialization of various kinds of intellectual property that we have largely discovered and acquired through the sales process associated with this segment.

Overview of our Products and Services

Products and Services Overview

Current products and services provided are as follows:

1 unchanged sentence

• TRU NIAGEN® branded dietary supplements.

We currently offer our NIAGEN® NR through our TRU NIAGEN® finished bottles.

We currently offer our NIAGEN® NR through our TRU NIAGEN® finished bottles and TRU NIAGEN® Stickpacks.

We will continue to build TRU NIAGEN® as a global brand and offer TRU NIAGEN® to consumers worldwide.

7 unchanged sentences

We supply a wide range of products necessary to conduct quality control of raw materials and consumer products.

Reference standards and fine chemicals are used for research and quality control in the dietary supplements, cosmetics, food and beverages, life science, and pharmaceutical industries.

Reference standards are used for research and quality control in the dietary supplements, cosmetics, food and beverages, life science, and pharmaceutical industries.

In addition, we provide research services for customers exploring the frontier of natural product research and development.

We assist by providing unique and well-characterized natural products, in the format of botanical libraries or as requested on custom “Scope of Work” request.

We assist by providing unique and well-characterized natural products, in the format of botanical libraries or as requested on custom “Scope of Work” requests.

Major Customers

For the years ended December 31, 2021 and 2020, we had one major customer which accounted for more than 10% of our total net sales.

Watson Group, a related party, accounted for approximately 13.8% and 13.0% of our net sales for the years ended December 31, 2021 and 2020, respectively.

Generally, we do not depend upon a single customer, or a few customers, and the loss of any one or more would not have a material adverse effect on the Company.

However, due to the volume of consumer products and ingredients we are selling in relation to the overall Company’s sales, we do expect that at times one or more of our customers may account for more than 10% of the Company’s sales.

Impact of COVID-19

The COVID-19 pandemic continues to drive global uncertainty and disruption, which has created headwinds for our business.

Our ecommerce consumer products business segment continues to perform relatively well in this challenging environment.

Our consumer products retail business, including sales to A.S.

Watson group and other partners in international markets, has been more impacted by the effects of COVID-19, due to store closures and reduced operating hours.

To date, we have successfully navigated the business during the COVID-19 pandemic, managing our working capital effectively.

We have experienced shipment delays from our suppliers;

however, we have not encountered any major disruptions in our supply chain.

We have been maintaining adequate safety stocks to support our growth and we currently have adequate inventory on hand to meet our current demands.

Overall, we believe the supply chain disruptions due to the COVID-19 pandemic will not have a material impact to our business operations.

In response to the outbreak, we prioritized the health and safety of our employees by closing our offices or enhancing safety protocols in place to ensure the well-being of our employees.

We have been able to successfully conduct business virtually.

The worldwide outbreak of COVID-19 continues to drive global uncertainty and disruption, which has created headwinds for our business.

Authorities have imposed, and businesses and individuals have implemented, numerous measures to try to contain the virus or treat its impact, such as travel bans and restrictions, quarantines, shelter-in-place/stay-at-home and social distancing orders, store closures and reduced operating hours, and vaccine requirements.

These measures have impacted and may further impact our workforce and operations and those of our respective suppliers and partners.

In particular, we have experienced, and could in the future experience, global supply chain delays including challenges with transportation, logistics and production lead-times, as well as labor shortages and cost inflation.

In the first quarter of 2021, we experienced delays due to global components and packaging shortages for our consumer products across our supply chain.

These challenges were addressed in the second quarter and we have otherwise not encountered any major disruptions in our supply chain.

It is our intention to maintain adequate safety stocks to support our growth and we currently believe we have adequate inventory on hand to meet current demands.

We will continue to monitor the situation closely as conditions may become more challenging due to ongoing and uncertain economic factors.

Additionally, our sales to partners in international markets have been impacted by the effects of COVID-19.

Our primary focus throughout the COVID-19 pandemic has remained ensuring the health and safety of our employees through office closures or implementing enhanced safety protocols to ensure the well-being of our employees.

We have adapted to the new environment and been able to successfully conduct business virtually.

The degree to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including the duration and severity of the pandemic;

surges related to new variants;

the actions taken to contain the virus or treat its impact;

other actions taken by governments, businesses, and individuals in response to the virus and resulting economic disruption;

and how quickly and to what extent normal economic and operating conditions can resume.

Additional impacts and risks may arise that we are not aware of or able to respond to effectively.

We are similarly unable to predict the extent of the impact of the pandemic on our customers, suppliers, and other partners, but a material effect on these parties could also materially adversely affect us.

The impact of COVID-19 can also exacerbate other risks discussed in this Risk Factors section and throughout this report.

Sales and Marketing Strategy

For our consumer products segment, we employ a variety of strategies to drive sales and consumer awareness of TRU NIAGEN®, including social media and internet advertising, managing websites, influencers, paid spokespersons and talent, events and tradeshows, e-mail, paid search, distribution of research publications and press releases.

For our consumer products segment, we employ a variety of strategies to drive sales and consumer awareness of TRU NIAGEN®, including social media and internet advertising, managing affiliate marketing, influencers, paid spokespersons and talent, events and trade shows, e-mail, paid search, distribution of research publications and press releases.

We also have a customer care department that handles day-to-day communications with our end customers addressing any needs or concerns related to our TRU NIAGEN® product.

1 unchanged sentence

We recruit and hire sales and marketing staff with appropriate commercial and scientific backgrounds.

For our consumer products segment, we distribute our TRU NIAGEN® products direct to consumers through our propriety ecommerce platform TRUNIAGEN.com, Amazon and other established internet marketplaces.

We also have specialty retailers and direct healthcare practitioners who are authorized resellers of TRU NIAGEN® in the U.S.

For our ingredients segment and analytical reference standards and services segment, we intend to continue to use a direct marketing approach in the U.S.

United States of America:

For our consumer products segment, we distribute our TRU NIAGEN® products direct to consumers through our propriety e-commerce platform TRUNIAGEN.com, Amazon, Walmart.com and other established internet marketplaces.

In June 2021, we began distributing Tru Niagen® in 3,800+ Walmart stores across the U.S.

We also have specialty retailers and direct healthcare practitioners who are authorized resellers of TRU NIAGEN® in the United States.

For our ingredients segment and analytical reference standards and services segment, we use a direct marketing approach in the United States.

to promote our products and services.

1 unchanged sentence

For our consumer products segment, we utilize strategic partners on a regional or local country basis to expand our distribution of TRU NIAGEN® products.

Our strategic partnerships include brick and mortar and/or ecommerce channels.

We began the international expansion of our TRU NIAGEN® brand with the launch in Hong Kong and Macau with our strategic partner, A.S.

Watson Group, in 2017, followed by the launch in Singapore in 2018.

We are currently selling cross border in China on Tmall, JD.com, Kaola.com and Wechat and on Amazon in Canada, Japan, the United Kingdom, Germany, France, Italy, Spain, Netherlands and Sweden.

With the TGA approval we extended our partnership with our New Zealand partner, Matakana Superfoods, to also include Australia.

We will continue to focus on obtaining additional regulatory approvals required to expand our marketing and distribution of our TRU NIAGEN® brand in new strategic international markets.

For our ingredients segment, most of our customers are based currently in the U.S.

For our analytical reference standards and services segment outside of the U.S., we use international distributors to market and sell to several foreign countries or markets.

Our strategic partnerships include brick and mortar, e-commerce channels or a combination of both.

With our strategic partners, we currently distribute TRU NIAGEN® products to the following international markets:

• Hong Kong (A.S.

Watson Group);

• Macau (A.S.

Watson Group);

• Singapore (A.S.

Watson Group);

• New Zealand (Matakana Superfoods);

• Canada (Amazon, Fullscript Canada and www.truniagen.ca);

• Australia (Matakana Superfoods);

• China (Tmall, JD.com and Wechat);

• Japan (Amazon);

• United Kingdom (Amazon);

• Germany (Amazon);

• France (Amazon);

• Italy (Amazon);

• Spain (Amazon);

• Poland (Amazon);

• Netherlands (Amazon);

• Sweden (Amazon).

We continue to focus on obtaining additional regulatory approvals required to expand marketing and distribution of our TRU NIAGEN® brand in new strategic international markets.

For our ingredients segment, currently our customers are primarily based in the United States and Europe.

For our analytical reference standards and services segment outside of the United States, we use international distributors to market and sell to several foreign countries or markets.

Sales and marketing expense for the years ended December 31, 2021 and 2020, were approximately $28.4 million and $20.9 million, respectively.

Research and Development

The ChromaDex External Research Program (CERP) is an essential component of our research and development platform.

CERP was established to advance the science of nicotinamide riboside and other ChromaDex products.

We value and encourage strong scientific rigor behind our products and have cultivated relationships with academic institutions in pursuit of this.

Thus far, CERP has achieved over 245 research partnership agreements with leading universities and research institutions around the world including the National Institutes of Health, Cornell, Dartmouth, Harvard, Massachusetts Institute of Technology, University of Cambridge and the Mayo Clinic.

Additional relationships are currently being developed.

To date, over 200 peer-reviewed studies have been published on the science behind NR, including its NAD+ boosting properties.

CERP has produced more than 45% of all peer-reviewed NR-focused publications and 70% of the peer-reviewed clinical NR publications so far.

To date, 20 peer-reviewed human clinical trials have been published on our proprietary ingredient NIAGEN® demonstrating its safety and/or efficacy through CERP.

No adverse effects have been attributed to NIAGEN® in any of the published clinical trials.

In both 2015 and 2018, NIAGEN® was successfully notified to the FDA as an NDI.

NIAGEN® was also successfully notified to FDA as Generally Recognized as Safe in August 2016.

Through our research and development laboratory in Longmont, Colorado, we intend to develop and evaluate products that we plan to take to market as well as explore cost saving processes for existing products.

Research and development costs for the years ended December 31, 2021 and 2020, were approximately $3.8 million and $3.4 million, respectively.

Working Capital

ChromaDex’s working capital as of December 31, 2021 and 2020 was approximately $8.4 million and $4.9 million, respectively.

We measure working capital by adding trade receivables and inventories, and subtracting accounts payable.

Our working capital is primarily comprised of assets and liabilities related to our consumer products segment and ingredients segment as the operations require a large amount of inventory on hand.

As the consumer products segment and ingredients segment grow, more working capital will likely be needed to support the operations.

Government Regulation

Some of our operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), the Department of Commerce, the Department of Transportation, the Department of Agriculture and other state and international agencies.

Some of our operations are subject to regulation by various U.S.

federal agencies and similar state and international agencies, including, but not limited to, the FDA, the Federal Trade Commission (FTC), the Department of Commerce, the Department of Transportation and the Department of Agriculture.

These regulators govern a wide variety of production activities, from design and development to labeling, manufacturing, handling, selling and distributing of products.

From time to time, federal, state and international legislation is enacted that may have the effect of materially increasing the cost of doing business or limiting or expanding our permissible activities.

From time to time, federal, state and international legislation is enacted that may materially increase our cost of doing business or may limit or expand our permissible activities.

We cannot predict whether or when potential legislation or regulations will be enacted, and, if enacted, the effect of such legislation, regulation, implementation, or any implemented regulations or supervisory policies would have on our financial condition or results of operations.

In addition, the outcome of any litigation, investigations or enforcement actions initiated by state or federal authorities could result in changes to our operations being necessary and in increased compliance costs.

In addition, the outcome of any litigation, investigations or enforcement actions initiated by state or federal authorities could result in required changes to our operations and increased compliance costs.

FDA Regulation

In the United States dietary supplements and food are subject to FDA regulations.

For example, the FDA’s final rule on Good Manufacturing Practices (“GMPs”) for dietary supplements published in June 2007 requires companies to evaluate products for identity, strength, purity and composition.

Other regulations, for new dietary ingredients (“NDI”), require a pre-market notification that must be submitted to the FDA along with evidence of safety.

In addition, depending on the type of product, whether a dietary supplement, cosmetic, food, or pharmaceutical, the FDA, under the Food, Drug and Cosmetic Act (the “FDCA”), can regulate:

In the U.S., dietary supplements and food are subject to FDA regulations under the Federal Food, Drug and Cosmetic Act (FDCA).

Areas addressed in these regulations include:

• product safety;

• product testing;

2 unchanged sentences

• product labeling;

• manufacturing facility registration;

• product manufacturing and storage;

4 unchanged sentences

DSHEA established a new framework for governing the composition and labeling of dietary supplements.

Generally, under DSHEA, dietary ingredients that were marketed in the United States before October 15, 1994, may be used in dietary supplements without notifying the FDA.

However, an NDI (a dietary ingredient that was not marketed in the United States before October 15, 1994) is subject to NDI notification that must be submitted to the FDA unless the ingredient has previously been “present in the food supply as an article used for food” without being “chemically altered.” An NDI notification must provide the FDA with evidence of a “history of use or other evidence of safety” establishing that the use of the dietary ingredient “will reasonably be expected to be safe.” An NDI notification must be submitted to the FDA at least 75 days before the initial marketing of the NDI.

Generally, under DSHEA, dietary ingredients that were marketed in the U.S.

before October 15, 1994, may be used in dietary supplements without notifying the FDA.

However, an NDI (a dietary ingredient that was not marketed in the U.S.

before October 15, 1994) is subject to an NDI notification that must be submitted to the FDA unless the ingredient has previously been “present in the food supply as an article used for food” without being “chemically altered.” An NDI notification must provide the FDA with evidence of a “history of use or other evidence of safety” establishing that the use of the dietary ingredient “will reasonably be expected to be safe.” An NDI notification must be submitted to the FDA at least 75 days before the initial marketing of the NDI.

There can be no assurance that the FDA will accept the evidence of safety for any NDIs that we may want to commercialize, and the FDA’s objection to such evidence could render products containing such dietary ingredients to be adulterated.

The FDA is in the process of developing guidance for the industry that will aim to clarify the agency’s interpretation of the NDI notification requirements, and this guidance may raise new and significant regulatory barriers for NDIs.

For any new ingredient developed by us to be used in conventional food or beverage products in the United States, the product either must be approved by the FDA as a food additive pursuant to a food additive petition (“FAP”) or be generally recognized as safe (“GRAS”).

The FDA is in the process of finalizing guidance for the industry that will aim to clarify the agency’s interpretation of the NDI notification requirements, and this guidance may raise new and significant regulatory barriers for NDIs.

For any new ingredient developed by us to be used in conventional food or beverage products in the U.S., the product either must be approved by the FDA as a food additive pursuant to a food additive petition or be generally recognized as safe (GRAS).

The FDA does not have to approve a company’s determination that an ingredient is GRAS.

However, a company can voluntarily notify the FDA of its own self-determination.

There can be no assurance that the FDA will approve any FAP for any ingredient that we may want to commercialize, or agree with our determination that an ingredient is GRAS, either of which could impact the marketing of such ingredient.

There can be no assurance that the FDA will approve any food additive petition for any ingredient that we may want to commercialize, or agree with our determination that an ingredient is GRAS, either of which could impact the marketing of such ingredient.

Advertising Regulations

In addition to FDA regulations, the FTC regulates the advertising of dietary supplements, foods, cosmetics, and over-the-counter (“OTC”) drugs.

In addition to FDA regulations, the FTC regulates the advertising of dietary supplements, foods, cosmetics, and over-the-counter drugs.

In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for failure to adequately substantiate claims made in advertising or for the use of false or misleading advertising claims.

These enforcement actions have often resulted in consent decrees and the payment of civil penalties, restitution, or both, by the companies involved.

We may be subject to regulation under various state and local laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and distribution of dietary supplements, foods, cosmetics and OTC drugs.

In addition, The National Advertising Division of the Council of Better Business Bureaus reviews national advertising for truthfulness and accuracy.

Additionally, state attorney's general and private plaintiff attorneys also regulate the advertising of dietary supplements, foods, cosmetics, and over-the-counter drugs through enforcement of state consumer protection laws.

State attorney’s general and, to a larger extent, private lawyers specializing in consumer class action litigation have instituted numerous enforcement actions against dietary supplement companies for failure to adequately substantiate claims made in advertising, for the use of false or misleading advertising claims, for underdosed products that don’t meet label claims and allegations related to product safety.

These actions have often resulted in consent decrees and the payment of civil penalties, restitution, or both, by the companies involved.

We are not aware of, or party to, any action by a state attorney general or consumer class action involving our products.

Further, The National Advertising Division of the Council of Better Business Bureaus reviews national advertising for truthfulness and accuracy.

The National Advertising Division of the Council of Better Business Bureaus uses a form of alternative dispute resolution, working closely with in-house counsel, marketing executives, research and development departments and outside consultants to decide whether claims have been substantiated.

2 unchanged sentences

Most countries, in particular major markets, have established regulations for (a) authorizing the introduction of novel ingredients to market in the food and/or dietary/food/health supplement sectors and (b) for allowing finished goods to be placed on the market for consumer access.

Typically, novel ingredients must go through an extensive safety review process (similar to the NDI notification process in the US) by a regulatory or scientific authoritative body.

Typically, novel ingredients must go through an extensive safety review process (similar to the NDI notification process in the U.S.) by a regulatory or scientific authoritative body.

Finished products typically must either be notified or registered (a limited approval process) with the relevant authorities.

5 unchanged sentences

Regulation in other major and established markets, including Canada, Japan, Brazil and Australia all maintain and enforce a clear regulatory framework for novel ingredients and dietary supplements (or their equivalent).

Major Customers

Major customers who accounted for more than 10% of the Company’s total sales were as follows:

Years Ended December 31

Major Customers

Watson Group - Related Party

Generally, we do not depend upon a single customer, or a few customers, and the loss of any one or more would not have a material adverse effect on the Company.

Competitive Business Conditions

For our consumer products segment, we are in direct competition with Elysium Health who offers a similar product to TRU NIAGEN®.

For our consumer products segment, we are in direct competition with Elysium Health who offers a similar product to TRU NIAGEN® and other providers of NAD+ boosting supplements.

There are also a few resellers of NIAGEN® as consumer products that are our customers.

We believe these resellers are focused on specific channels that we believe are complementary to our business.

We believe these resellers are focused on specific channels that we feel are complementary to our business.

We also face strong indirect competition from other ingredient suppliers who may supply alternative ingredients that may have similar characteristics to ingredients we offer.

5 unchanged sentences

• Lonza Group Ltd (Switzerland)

Sabinsa Corporation (India/USA)

• Sabinsa Corporation (India/U.S.)

For the analytical reference standards and services segment, we face competition within the standardization and quality testing niche of the markets we serve.

3 unchanged sentences

Analytical Reference Standards and Services Segment Competitors

MilliporeSigma (USA)

Phytolab (Germany)

US Pharmacopoeia (USA)

• MilliporeSigma (U.S.)

• LGC Standards Ltd.

• US Pharmacopoeia (U.S.)

• Extrasynthese (France)

4 unchanged sentences

The following table sets forth our existing patents and those to which we have licensed rights:

Patent Number

Potent immunostimulants from microalgae

Licensed from University of Mississippi

Methods and compositions for treating neuropathies

Licensed from Washington University

Potent immunostimulatory extracts from microalgae

Licensed from University of Mississippi

Nicotinyl Riboside Compositions and Methods of Use

Licensed from Cornell University

Yeast strain and method for using the same to produce Nicotinamide Riboside

Licensed from Dartmouth College

Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform

Licensed from the University of Mississippi and U.S.

Patent Number Title Filling Date Issued Date Expires Licensor

7,205,284 Potent immunostimulants from microalgae 7/10/2001 4/17/2007 3/9/2022 Licensed from University of Mississippi

7,776,326 Methods and compositions for treating neuropathies 6/3/2005 8/17/2010 6/24/2026 Licensed from Washington University

7,846,452 Potent immunostimulatory extracts from microalgae 7/28/2005 12/7/2010 7/28/2025 Licensed from University of Mississippi

8,106,184 Nicotinyl Riboside Compositions and Methods of Use 11/17/2006 1/31/2012 9/20/2027 Licensed from Cornell University

8,114,626 Yeast strain and method for using the same to produce Nicotinamide Riboside 3/26/2009 2/14/2012 1/5/2026 Licensed from Dartmouth College

8,133,917 Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform 10/25/2010 3/13/2012 8/18/2025 Licensed from the University of Mississippi and U.S.

Department of Agriculture

Nicotinamide Riboside Kinase compositions and Methods for using the same

Licensed from Dartmouth College

Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform

Licensed from the University of Mississippi and U.S.

8,197,807 Nicotinamide Riboside Kinase compositions and Methods for using the same 4/20/2006 6/12/2012 11/19/2026 Licensed from Dartmouth College

8,252,845 Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform 2/1/2012 8/28/2012 8/18/2025 Licensed from the University of Mississippi and U.S.

Department of Agriculture

Nicotinamide Riboside Kinase compositions and Methods for using the same

Licensed from Dartmouth College

Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration

Licensed from the University of Mississippi and U.S.

8,383,086 Nicotinamide Riboside Kinase compositions and Methods for using the same 4/12/2012 2/26/2013 4/20/2026 Licensed from Dartmouth College

8,809,400 Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration 8/8/2011 8/19/2014 10/2/2028 Licensed from the University of Mississippi and U.S.

Department of Agriculture

Method for treating non-melanoma skin cancer by inducing UDP-Glucuronosyltransferase activity using pterostilbene

Co-owned by ChromaDex and University of California

Methods and compositions for treating neuropathies

Licensed from Washington University

Nicotyl riboside compositions and methods of use

Licensed from Cornell University

Method improve spatial memory via pterostilbene administration

Licensed from the University of Mississippi and U.S.

8,841,350 Method for treating non-melanoma skin cancer by inducing UDP-Glucuronosyltransferase activity using pterostilbene 5/8/2012 9/23/2014 5/8/2032 Co-owned by ChromaDex and University of California

8,889,126 Methods and compositions for treating neuropathies 5/28/2010 11/18/2014 6/3/2025 Licensed from Washington University

9,000,147 Nicotyl riboside compositions and methods of use 1/17/2012 4/7/2015 11/17/2026 Licensed from Cornell University

9,028,887 Method improve spatial memory via pterostilbene administration 5/22/2014 5/12/2015 6/10/2028 Licensed from the University of Mississippi and U.S.

Department of Agriculture

Methods and compositions for treating neuropathies

Licensed from Washington University

Nicotyl riboside compositions and methods of use

Licensed from Cornell University

Anxiolytic effect of pterostilbene

Licensed from the University of Mississippi and U.S.

9,295,688 Methods and compositions for treating neuropathies 10/10/2014 3/29/2016 6/3/2025 Licensed from Washington University

9,321,797 Nicotyl riboside compositions and methods of use 11/17/2014 4/26/2016 11/17/2026 Licensed from Cornell University

9,439,875 Anxiolytic effect of pterostilbene 5/11/2011 9/13/2016 12/11/2031 Licensed from the University of Mississippi and U.S.

Department of Agriculture

Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof

Co-owned by ChromaDex and The Queen’s University of Belfast

9,975,915 Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof 11/10/2017 5/22/2018 11/10/2037 Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

10,000,519 Methods of Preparing Nicotinamide Riboside and Derivatives Thereof 7/24/2014 6/19/2018 7/24/2034 Licensed from The Queen’s University of Belfast

10,000,520 B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof 3/16/2017 6/19/2018 3/16/2037 Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

Patent Number Title Filling Date Issued Date Expires Licensor

10,183,036 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors 4/20/2017 1/22/2019 4/20/2037 Owned by ChromaDex

10,280,190 Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions 3/16/2016 5/7/2019 5/31/2036 Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

10,688,118 Nicotinamide riboside compositions for topical use in treating skin conditions 10/30/2014 6/23/2020 4/6/2035 Owned by ChromaDex

10,689,411 Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof 11/10/2017

Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

10,815,262 Methods of preparing nicotinamide riboside and derivatives thereof

Licensed from The Queen’s University of Belfast

B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof

Co-owned by ChromaDex and The Queen’s University of Belfast

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors

Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Owned by ChromaDex

Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions

Co-owned by ChromaDex and The Queen’s University of Belfast

10,934,322 B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof

Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

11,033,568 Nicotinamide riboside compositions for topical use in treating skin conditions

Owned by ChromaDex

Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof

Co-owned by ChromaDex and The Queen’s University of Belfast

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided

11,071,747 Use of NAD precursors for breast enhancement

Licensed from University of Iowa

11,214,589 Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereof

Owned by ChromaDex

11,242,364 Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof

Co-owned with The Queen’s University of Belfast and exclusively licensed by ChromaDex

Manufacturing

We currently utilize third-party manufacturers to produce and supply dietary supplement, ingredients, products, and services.

We currently utilize third-party manufacturers to produce NR, encapsulate and bottle NR sold as a dietary supplement and produce and supply other ingredients, products, and services.

Following the receipt of products or product components from third-party manufacturers, we inspect and ensure conformance of each product and product component to our specifications.

We will also consider manufacturing certain products or product components internally, if our capacity permits, when demand or quality requirements make it appropriate to do so.

We intend to work with manufacturing companies that can meet the standards imposed by the FDA, the International Organization for Standardization and the quality standards that we will require for our own internal policies and procedures.

We expect to monitor and manage supplier performance through a corrective action program developed by us.

We work with manufacturing companies that can meet the standards imposed by the FDA, the International Organization for Standardization and the quality standards that we require for our own internal policies and procedures.

We monitor and manage supplier performance through a corrective action program developed by us.

We believe these manufacturing relationships can minimize our capital investment, help control costs, and allow us to compete with larger volume manufacturers of dietary supplements, phytochemicals and ingredients.

(Grace) is the Company’s exclusive manufacturer for the supply of NR.

Effective as of September 17, 2020, the Company entered into a Sixth Amendment (the “Sixth Amendment”) to the Manufacturing and Supply Agreement (such agreement as amended, the “Grace Manufacturing Agreement”), originally effective in January 2016 with Grace.

In January 2019, Grace was issued patents related to the manufacturing of the crystalline form of NR (the “Grace Patents”).

Pursuant to the Sixth Amendment, the Grace Manufacturing Agreement expires on December 31, 2021, subject to additional two-year renewal periods to be negotiated by the parties.

In addition, the Grace Manufacturing Agreement may be terminated by (a) the Company by providing 12 months’ notice prior to the end of the current term, (b) Grace by providing 12 months’ notice of its intent to cease manufacture of NR (a “Market Exit”) and (c) a party in the case of (1) a material breach by the other party that is not cured within 30 days, (2) three material breaches by the other party in any 12 month period, or (3) bankruptcy of the other party.

In the event that certain conditions are met, then the Company will become a licensee of the Grace Patents.

Effective as of August 2, 2021, we entered into a Seventh Amendment (Seventh Amendment) to the Manufacturing and Supply Agreement (such agreement as amended, the “Grace Manufacturing Agreement”), originally effective in January 2016 with Grace.

In January 2019, Grace was issued patents related to the manufacturing of the crystalline form of NR.

Pursuant to the Seventh Amendment, the Grace Manufacturing Agreement expires on June 30, 2023, subject to its further renewal to be negotiated by the parties.

Sources and Availability of Raw Materials

For all three business segments, and subject to the risks related to our Company and our business recited below, we believe that we have identified reliable sources and suppliers of ingredients, chemicals, phytochemicals and reference materials that will provide products in compliance with our guidelines.

Research and Development

To date, 11 human clinical trials have been published on our proprietary ingredient NIAGEN® demonstrating its safety and/or efficacy in healthy human volunteers.

In addition, no adverse effects have been attributed to NIAGEN®.

In both 2015 and 2018, NIAGEN® was successfully notified to the FDA as a “New Dietary Ingredient.” NIAGEN® was also successfully notified to FDA as “Generally Recognized as Safe” in August 2016.

In June of 2020, the ChromaDex External Research Program (CERP) achieved its 200 th research agreement and over 100 preclinical studies and 11 peer-reviewed human clinical trial publications involving NIAGEN® .

Through our research and development laboratory in Longmont, Colorado, we intend to develop and evaluate products that we are planning to take to market as well as explore cost saving processes for existing products.

Research and development costs for the fiscal years ended December 31, 2020, and December 31, 2019, were approximately $3.7 million and $4.4 million, respectively.

Environmental Compliance

We incur significant expense in complying with GMPs and safe handling and disposal of materials used in our research and manufacturing activities.

We incur significant expense in complying with Good Manufacturing Practices and safe handling and disposal of materials used in our research and manufacturing activities.

For the years ended December 31, 2021 and 2020, these expenses totaled approximately $1.7 million and $1.5 million, respectively.

We do not anticipate incurring additional material expense to comply with federal, state and local environmental laws and regulations.

Working Capital

The Company’s working capital at the end of years 2020 and 2019 was approximately $4.9 million and $4.1 million, respectively.

The Company measures working capital by adding trade receivables and inventories, and subtracting accounts payable.

Most of the working capital is consumed by our consumer products segment and ingredients segment as the operations require a large amount of inventory to be on hand.

As the consumer products segment and ingredients segment grow, more working capital will likely be needed to support the operations.

Backlog Orders

3 unchanged sentences

For our ingredients segment, we also have minimal backlog orders as we carry inventory on hand for most of the products we offer and we ship upon the receipt of customer’s order.

For our analytical reference standards and services segment, we normally have a small backlog of orders for reference standards.

For our analytical reference standards and services segment, we normally have a small backlog of orders.

These orders amount to approximately $20,000 or less.

Because we list over 3,000 phytochemicals and 300 botanical reference materials in our catalog, we may not always have the items in stock at the time of customers’ orders.

These backlog orders are normally fulfilled within 2 to 3 months.

These backlog orders are normally fulfilled within two to four weeks.

Culture and Workforce

We’re a company of curious, talented, and passionate people who are devoted to health, well-being, and improving the way people age.

We embrace collaboration and creativity and encourage the iteration of ideas to address complex challenges in all aspects of our business.

We believe our people are critical for our success.

We are dedicated to providing an environment where ChromaDex employees can have fulfilling careers, and be happy, healthy and productive.

We offer attractive wage and benefit packages to take care of the needs of our employees and their families.

Our competitive compensation and dynamic culture help us to attract and retain top candidates.

We continue to invest in recruiting and rewarding talented people.

ChromaDex and its employees are dedicated to diversity, inclusion, and fairness.

We celebrate personal authenticity and expression as a catalyst to advance human health and innovation.

We support healthy, open dialogue and we communicate information about the company through multiple internal channels to our employees .

As of December 31, 2021, ChromaDex had 115 full-time employees.

For information on our facilities, see “Properties” in Item 2 of this Form 10-K.

As of December 31, 2020, ChromaDex had approximately 110 employees.

We consider our relationships with our employees to be satisfactory.

None of our employees is covered by a collective bargaining agreement.

Financial Information about Geographic Areas

Please refer to Item 8 Financial Statements and Supplementary Data of this Annual Report on Form 10-K for financial information about geographic areas.

Available Information

Our Internet website address is www.chromadex.com.

Our website address is www.chromadex.com .

Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K.

We make available free of charge on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practical after we file such material with, or furnish it to, the Securities and Exchange Commission.

We make available, free of charge, on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practical after we file such material with, or furnish it to, the SEC.

This information is also available in print to any stockholder who requests it, with any such requests addressed to ChromaDex Corporation, 10900 Wilshire Blvd.

1 unchanged sentence

Certain of these documents may also be obtained by calling the SEC at 1-800-SEC-0330.

The SEC also maintains an Internet website that contains reports, and other information regarding issuers that file electronically with the SEC at www.sec.gov.

The SEC also maintains a website that contains reports, and other information regarding issuers that file electronically with the SEC at www.sec.gov .

We also make available, free of charge, on our website our Code of Business Conduct and Ethics, and the Charters of our Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee of our Board of Directors.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business